AR and prostate carcinoma: Further analysis using prostate cancer gold peak datasets (detailed in the Experimental Section) found that RECWAS identified 3 novel AR and 6 H3K27ac gold peaks, in contrast to CWAS which identified only one H3K27ac gold peak within these datasets (Figure 4B).